Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIIIW) Cash & Equivalents (2019 - 2025)

P3 Health Partners' Cash & Equivalents history spans 7 years, with the latest figure at $25.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 35.57% year-over-year to $25.0 million; the TTM value through Dec 2025 reached $25.0 million, down 35.57%, while the annual FY2025 figure was $25.0 million, 35.57% down from the prior year.
  • Cash & Equivalents reached $25.0 million in Q4 2025 per PIIIW's latest filing, down from $37.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $110.3 million in Q1 2022 to a low of $4.3 million in Q3 2021.
  • Average Cash & Equivalents over 5 years is $38.7 million, with a median of $37.0 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 692.27% in 2022, then tumbled 93.48% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $5.3 million in 2021, then skyrocketed by 230.13% to $17.5 million in 2022, then skyrocketed by 107.54% to $36.3 million in 2023, then rose by 6.83% to $38.8 million in 2024, then plummeted by 35.57% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for PIIIW's Cash & Equivalents are $25.0 million (Q4 2025), $37.7 million (Q3 2025), and $38.6 million (Q2 2025).